Pharmacotherapy Alignment with Patient-Defined Goals in Critical Care
Learning Objective
Design a pharmacotherapy plan that aligns with patient-defined goals of care and documented advance directives in the critical care setting.
1. Assessing Appropriateness of Life-Sustaining Therapies
Continuously reevaluating invasive or supportive therapies against evolving patient goals is a cornerstone of ethical critical care. When curative measures conflict with advance directives or patient and family wishes, the focus must shift from life prolongation to symptom control and comfort.
A. Curative vs. Comfort-Focused Goals
The primary intent of care dictates the aggressiveness of pharmacotherapy. This table contrasts the two primary approaches.
| Therapeutic Domain | Curative Intent | Comfort-Focused Intent |
|---|---|---|
| Hemodynamics | Prioritize organ perfusion; target MAP ≥65 mmHg with vasopressors. | Prioritize relief from symptoms of hypoperfusion; taper vasopressors to lowest dose that maintains comfort and mentation. |
| Antimicrobials | Use broad-spectrum agents for suspected sepsis; de-escalate based on culture data. | Use only if treating infection provides symptom relief (e.g., fever). Discontinue if burden outweighs benefit. |
| Ventilation | Provide full ventilatory support to correct hypoxemia and acidosis. | Use minimal settings to relieve dyspnea; prioritize weaning or withdrawal if discordant with patient wishes. |
| Primary Goal | Survival and recovery of organ function. | Relief of pain, dyspnea, and anxiety; quality of remaining life. |
Clinical Pearl: Goal-Concordant Thresholds
In comfort-focused care, agents that solely prolong life without providing symptom benefit should be considered for withdrawal. Documenting explicit thresholds (e.g., “taper vasopressors if MAP > 60 mmHg and patient is comfortable”) provides clear guidance for the bedside team and helps ensure therapies are aligned with pre-specified goals.
B. Vasopressors
The use of vasopressors must directly reflect patient goals. They may be used to support organ function for a trial period, provide temporary support for symptom relief, or extend life if consistent with advance directives. Their use should be re-evaluated daily.
C. Antimicrobials
Empiric and definitive antimicrobial use should balance infection control against the discomfort or burden of therapy when comfort is the primary goal. Initiate broad-spectrum therapy for suspected sepsis if curative intent or symptom relief (e.g., fever reduction) is desired. De-escalation should be assessed at 48–72 hours based on hemodynamic stability, pathogen data, and biomarker trends.
Controversy: Antibiotic Discontinuation
The timing of antibiotic discontinuation in cases of unclear infection remains debated. Some clinicians favor brief, symptom-directed therapy, while others advocate for maintaining coverage to avoid the risk of undertreatment. This decision requires careful discussion with the patient or surrogate decision-maker about the potential benefits versus burdens.
Clinical Pearl: Stewardship in Comfort Care
Even in comfort care, antimicrobial stewardship is important. Aim to narrow the spectrum to the most targeted agent once susceptibilities are known to minimize side effects. Involving clinical pharmacists in stewardship rounds can help prevent unnecessary broad-spectrum exposure and identify opportunities for de-escalation.
D. Mechanical Ventilation
Decisions to initiate, continue, or withdraw mechanical ventilation must align with patient directives. If the prolongation of life via mechanical support offers no curative or comfort benefit, its use may be limited or withdrawn in a structured, symptom-managed process.
2. Sedation and Analgesia for Comfort-Focused Care
In comfort-focused care, analgosedation prioritizes opioid-driven relief of pain and dyspnea before adding sedatives. Agent selection and titration must account for organ dysfunction to maximize comfort and minimize adverse effects.
A. Opioids for Pain and Dyspnea
Opioids like morphine and fentanyl are first-line agents for managing pain and the sensation of dyspnea in critically ill patients. They act as mu-receptor agonists, modulating the central perception of these distressing symptoms.
- Initiation: Start with low, as-needed doses (e.g., morphine 2–5 mg IV q2h PRN; fentanyl 25–50 mcg IV q1h PRN). Continuous infusions may be used for persistent symptoms.
- Titration: Increase doses by 25–50% based on validated symptom scales (e.g., Behavioral Pain Scale for pain, numeric rating for dyspnea).
- PK Adjustments: In renal impairment, the active metabolite of morphine accumulates; fentanyl is preferred. In hepatic dysfunction, reduce doses of both agents and monitor closely.
Clinical Pearl: Titrating Opioids for Dyspnea
Titrate opioids to the lowest effective dose that provides relief from dyspnea. Doses that exceed this comfort threshold rarely add benefit and significantly increase the risk of over-sedation and respiratory depression without improving the patient’s experience.
B. Sedative Agents
When opioids alone are insufficient to manage anxiety or agitation, sedative agents are added. Non-benzodiazepine sedatives are generally preferred to minimize delirium.
| Agent | Key Features | Common Adverse Effects | Organ Dysfunction Considerations |
|---|---|---|---|
| Propofol | Rapid onset/offset, ideal for procedural sedation or daily interruption. | Hypotension, hypertriglyceridemia, propofol-related infusion syndrome (PRIS). | No adjustment in mild renal/hepatic impairment. Use with caution in severe shock. |
| Dexmedetomidine | Light, cooperative sedation with anxiolysis and modest analgesia. Does not suppress respiratory drive. | Bradycardia, hypotension. | Metabolized hepatically. Reduce dose in severe liver disease. No renal adjustment needed. |
| Midazolam | Potent anxiolytic and amnestic. Provides deeper sedation. | Prolonged sedation, delirium, respiratory depression. Risk of accumulation. | Active metabolites accumulate in renal failure. Avoid or reduce dose significantly in both renal and hepatic failure. |
3. Pharmacokinetic and Pharmacodynamic Adjustments
Critical illness and organ support therapies profoundly alter drug clearance and distribution. Individualizing dosing is essential to avoid toxicity while ensuring comfort.
A. Renal Impairment
Renal dysfunction necessitates dose reduction for many drugs. Decrease doses for renally excreted opioids (e.g., morphine metabolites) and hydrophilic antibiotics (e.g., beta-lactams, vancomycin). Remember to account for drug removal by continuous renal replacement therapies (CRRT), which can clear low-molecular-weight, unbound drugs.
B. Hepatic Dysfunction
For patients with liver failure, prefer agents with organ-independent metabolism (e.g., remifentanil, cisatracurium) or those with predictable clearance (e.g., hydromorphone). Standard agents like propofol and dexmedetomidine should be used with caution, often requiring dose reduction and careful monitoring.
4. De-escalation and Withdrawal Protocols
Structured tapering of life-sustaining or symptom-modifying drugs is critical to prevent withdrawal symptoms and rebound distress. All de-escalation plans must be tailored to comfort-oriented goals and communicated clearly among the care team.
A. Antimicrobial De-escalation Pathways
A systematic approach to antimicrobial de-escalation is a key component of antibiotic stewardship and goal-concordant care.
5. Fluid and Nutritional Management
In comfort-focused care, hydration and nutrition should be provided to relieve the sensations of thirst and hunger without exacerbating symptoms like edema or dyspnea.
A. Goals of Hydration in Comfort Care
The primary goal is patient comfort, not physiologic correction. This often means providing minimal effective fluids (e.g., 500–1,000 mL/day) to alleviate thirst while avoiding the negative consequences of fluid overload. Whenever possible, meticulous mouth care, ice chips, or small sips of water are preferred over large-volume IV infusions, as they directly address the sensation of a dry mouth with less systemic impact.
6. Interprofessional Collaboration and Decision Support
Ensuring goal-concordant pharmacotherapy is a team effort. Clinical pharmacists play a key role in medication reviews, protocol development, and providing real-time decision support. Regular case conferences involving physicians, nurses, pharmacists, and palliative care specialists are essential for aligning the care plan with the patient’s evolving goals.
References
- Barlam TF, Cosgrove SE, Abbo LM, et al. Antibiotic stewardship in the intensive care unit. Ann Am Thorac Soc. 2020;17(3):276–283.
- Kollef MH, Micek ST, Hampton N, et al. Principles and practice of antibiotic stewardship in the ICU. Crit Care Med. 2019;47(1):1–8.
- Roberts JA, Neely MN, Udy AA, Hope WW. Pharmacokinetic alterations associated with critical illness. Pharmaceutics. 2023;15(2):345.
- Schuts EC, Hulscher ME, Mouton JW, et al. Antimicrobial stewardship and ICU mortality: systematic review and meta-analysis. Clin Infect Dis. 2019;68(5):748–756.
- Seo Y, Paik HC, Oh JY, et al. KSCCM practice guidelines for pain, agitation, delirium, immobility, and sleep disruption in critically ill patients. Acute Crit Care. 2022;37(1):1–25.
- Tabah A, Koulenti D, Laupland KB, et al. Antimicrobial de-escalation in critically ill patients: ESICM/ESCMID position statement. Intensive Care Med. 2020;46(2):245–257.
- Tanzarella ES, De Rosa FG, Cutuli SL, et al. Antimicrobial de-escalation in critically ill patients. Antibiotics (Basel). 2024;13(4):678.
- MacLaren PRN. Pharmacotherapy alignment with patient-defined goals in critical care. 2023.
